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Celiac Disease and the Gluten-Free Diet: How Much is Too Much of a
Gluten Thing?
Abstract
Celiac disease is being recognized and diagnosed more frequently with the help of improved serologic
indicators and biopsy techniques. With dietary intervention being the only definitive treatment, more
research is needed to define the potentially toxic threshold of gluten marking the amount that prevents
intestinal histological recovery. In addition, with a dietary noncompliance rate estimated at greater than 50%,
more research needs to be done on influencing factors and issues surrounding the difficulties of dietary
compliance.
Background: Celiac disease (CD) has an intensely complex pathophysiology that involves both environmental
factors and genetic components. It is identified by the inability to ingest gluten without having an immune
response in genetically susceptible patients. Research has indicated that genetic susceptibility alone does not
result in CD, that there is a certain environmental aspect that must be present as well. With the right genetics
and environmental exposure, gluten ingestion will cause intestinal inflammation, villous atrophy, and
flattening of the intestinal mucosa.
There are many approaches to diagnosing celiac disease. While small bowel biopsy remains the gold standard
for diagnosis, serologic tests are still the initial part of the evaluation. The most sensitive and specific tests
currently available are the immunoglobulin A anti tissue transglutaminase (IgA tTG) and IgA endomysial
antibody (IgA EMA). In the rare circumstance that a patient is IgA deficient, however, these serologies are
unreliable and an IgG based assay must be used.
The only definitive treatment for celiac disease is to remove gluten from the diet. The problem is there is no
defined threshold of gluten contamination and the potential toxicity of even trace amounts remains unclear.
Patients need to first understand which products contain gluten, maintain strict adherence to the diet, and
continue periodic follow up with both a celiac trained registered dietitian and their primary care provider. As
more people are being diagnosed with celiac disease, more gluten free products are becoming available.
Additionally, more research is being done on the effects of the gluten free diet with regards to its effect on
intestinal mucosa as well as its psychosocial effect on the patient.
Codex Alimentarius was established in the 1960’s by the World Health Organization and the Food and
Agriculture Organization of the United Nations as a way of formulating and implementing food safety
standards worldwide. A Spanish doctor devised and presented to the organization an enzyme-linked
immunosorbent assay (ELISA) method of detecting gluten levels as low as 3.2 parts per million (ppm). And
while more studies are needed, current research can be used to temporarily deduce a safe daily gluten
threshold. Exposure to gluten on a gluten free diet (GFD) is not as easily measured as there is limited data
available on the consumption of gluten free products as well as to what degree patients substitute traditional
bread, pasta, and other cereal based products for the their gluten free alternatives.
Objective: To establish an upper limit of potentially toxic gluten levels for celiac patients and to uncover the
factors that negatively impact gluten free dietary compliance.
Methods: An extensive online search was done using Ovid, PubMed, and UpToDate. Search terms used were
Celiac disease, gluten-free diet, gluten threshold, quality of life, dietary compliance. Articles were limited to
human subjects and those written in English and published within the last five years.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/185
Results: Studies continue to have varying results but current research suggests that 30-50 mg of ingested
gluten per day can be considered safe clinically and histologically for people who suffer with Celiac disease.
This is roughly 100-160 parts per million of gluten. Even if celiac patients tried to abide by the most recent
findings however, there are no current guidelines in the United States regulating labeling indicating gluten
content. The only safe approach is to consume fruits, vegetables, and meat while adding moderate ‘gluten-free’
products as the gluten content is not yet regulated.
Dietary compliance was shown to be difficult for a multitude of reasons. Women tend to adhere to the
required diet more often than men, but also have been found to have higher rates of anxiety, depression, and
lower self-rated quality of life scores. Cost analysis indicated that gluten-free products cost approximately
three times their regular wheat-based counterpart.
Conclusion: Maintaining a gluten-free diet is difficult and can be costly. Maintaining gluten intake between
30-50 mg per day appears to be safe. Insuring gluten intake remains at that level, consumption should be
mostly fruits, vegetables, and meat with minimal addition of store bought gluten-free products. No study has
been done evaluating the effect of gluten-free product cost on dietary compliance but with the results of the
cost analysis, it can be implied that this added burden would likely have a negative impact. Increased product
availability at more reasonable prices would likely improve adherence. Finally, there is an increased need for
improved dietary instruction as well as support for celiac patients in order to help ease or even alleviate
anxiety and other issues surrounding dietary compliance.
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Abstract   
 
Celiac disease is being recognized and diagnosed more frequently with the help of 
improved serologic indicators and biopsy techniques. With dietary intervention being the 
only definitive treatment, more research is needed to define the potentially toxic 
threshold of gluten marking the amount that prevents intestinal histological recovery. In 
addition, with a dietary noncompliance rate estimated at greater than 50%, more research 
needs to be done on influencing factors and issues surrounding the difficulties of dietary 
compliance.   
 
Background:  
Celiac disease (CD) has an intensely complex pathophysiology that involves both 
environmental factors and genetic components. It is identified by the inability to ingest 
gluten without having an immune response in genetically susceptible patients. Research 
has indicated that genetic susceptibility alone does not result in CD, that there is a certain 
environmental aspect that must be present as well. With the right genetics and 
environmental exposure, gluten ingestion will cause intestinal inflammation, villous 
atrophy, and flattening of the intestinal mucosa.   
 
There are many approaches to diagnosing celiac disease. While small bowel biopsy 
remains the gold standard for diagnosis, serologic tests are still the initial part of the 
evaluation.  The most sensitive and specific tests currently available are the 
immunoglobulin A anti tissue transglutaminase (IgA tTG) and IgA endomysial antibody 
(IgA EMA). In the rare circumstance that a patient is IgA deficient, however, these 
serologies are unreliable and an IgG based assay must be used.  
 
The only definitive treatment for celiac disease is to remove gluten from the diet. The 
problem is there is no defined threshold of gluten contamination and the potential toxicity 
of even trace amounts remains unclear. Patients need to first understand which products 
contain gluten, maintain strict adherence to the diet, and continue periodic follow up with 
both a celiac trained registered dietitian and their primary care provider.  As more people 
are being diagnosed with celiac disease, more gluten free products are becoming 
available. Additionally, more research is being done on the effects of the gluten free diet 
with regards to its effect on intestinal mucosa as well as its psychosocial effect on the 
patient.  
 
Codex Alimentarius was established in the 1960’s by the World Health Organization and 
the Food and Agriculture Organization of the United Nations as a way of formulating and 
implementing food safety standards worldwide. A Spanish doctor devised and presented 
to the organization an enzyme-linked immunosorbent assay (ELISA) method of detecting 
gluten levels as low as 3.2 parts per million (ppm). And while more studies are needed, 
current research can be used to temporarily deduce a safe daily gluten threshold. 
Exposure to gluten on a gluten free diet (GFD) is not as easily measured as there is 
limited data available on the consumption of gluten free products as well as to what 
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degree patients substitute traditional bread, pasta, and other cereal based products for the 
their gluten free alternatives.1 
 
Objective: To establish an upper limit of potentially toxic gluten levels for celiac patients 
and to uncover the factors that negatively impact gluten free dietary compliance.   
 
Methods: An extensive online search was done using Ovid, PubMed, and UpToDate. 
Search terms used were Celiac disease, gluten-free diet, gluten threshold, quality of life, 
dietary compliance. Articles were limited to human subjects and those written in English 
and published within the last five years.  
 
Results: Studies continue to have varying results but current research suggests that 30-50 
mg of ingested gluten per day can be considered safe clinically and histologically for 
people who suffer with Celiac disease. This is roughly 100-160 parts per million of 
gluten. Even if celiac patients tried to abide by the most recent findings however, there 
are no current guidelines in the United States regulating labeling indicating gluten 
content. The only safe approach is to consume fruits, vegetables, and meat while adding 
moderate ‘gluten-free’ products as the gluten content is not yet regulated.  
Dietary compliance was shown to be difficult for a multitude of reasons. Women tend to 
adhere to the required diet more often than men, but also have been found to have higher 
rates of anxiety, depression, and lower self-rated quality of life scores. Cost analysis 
indicated that gluten-free products cost approximately three times their regular wheat-
based counterpart.  
 
Conclusion: Maintaining a gluten-free diet is difficult and can be costly. Maintaining 
gluten intake between 30-50 mg per day appears to be safe. Insuring gluten intake 
remains at that level, consumption should be mostly fruits, vegetables, and meat with 
minimal addition of store bought gluten-free products. No study has been done evaluating 
the effect of gluten-free product cost on dietary compliance but with the results of the 
cost analysis, it can be implied that this added burden would likely have a negative 
impact. Increased product availability at more reasonable prices would likely improve 
adherence. Finally, there is an increased need for improved dietary instruction as well as 
support for celiac patients in order to help ease or even alleviate anxiety and other issues 
surrounding dietary compliance.  
 
Keywords: Celiac disease, gluten-free diet, gluten threshold, quality of life, dietary 
compliance. 
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Introduction 
Celiac disease (CD) and the gluten-free diet (GFD) are increasingly getting more attention on the 
medical front as well as from consumers.  The US Food and Drug Administration has defined “gluten-
free” and by August 2008 will be regulating the use of this definition with regards to labeling.  
Ingredient lists must still be investigated by the consumer as gluten containing products will not be 
explicitly labeled as such. The FDA will use 20 parts per million (ppm) as the cutoff, as current 
literature suggest this is a reasonable limit of gluten exposure, until the proposed assessment of a safe 
gluten threshold can be completed. Dietary exclusion of gluten is the only definitive treatment of celiac 
disease. With an increasing amount of information on celiac disease and gluten-free diets why is there 
so much noncompliance? 
Background 
In the general population, celiac disease occurs in approximately 1 out of 133 people.  Having a first or 
second degree relative with CD increases the prevalence to 1 in 22 and 1 in 39, respectively.2 About 
97% of patients with CD have the genetic marker HLA-DQ2 and HLA-DQ8. Presence of this marker 
alone isn’t sufficient to develop CD as environmental factors play a significant role as well.  While 
simply having this HLA marker doesn’t mean CD is inevitable, the absence of it virtually rules it out.  
The environmental aspect of CD is the ingestion of gluten. Gluten is the protein element derived from 
barley, rye, and wheat that is rich in proline and glutamine which are both poorly digested by humans. 
Gliadin, an alcohol-soluble portion of gluten, is what contains most of the toxic compounds of gluten. 
The problem occurs when pancreatic and brush border proteases are unable to degrade the gliadin and 
therefore remain in the intestinal lumen. This coincides with the increased intestinal permeability of 
either a simultaneous infection or from the breakdown of the epithelial barrier that occurs with CD, 
mounting a T-cell mediated immune response.3  
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The most likely explanation for the HLA association is that the gliadin peptide attaches to the antigen-
presenting cells expressing the HLA-DQ allele. Tissue transglutaminase, an enzyme found at the 
epithelial brush border as well as the subepithelial brush border, has been found to increase the binding 
affinity of these gliadin peptides.  
The HLA alleles on the surface of antigen-presenting cells present the deamidated gliadin peptide to 
the CD4+T cell. In response to the gliadin peptide/HLA gene complex, the CD4+T cells release a vast 
number of cytokines, such as interferon gamma, interleukin 4, and tumor necrosis factor alpha, leading 
to the tissue damage that defines celiac disease: villous atrophy and crypt hyperplasia. This complex 
also stimulates B cells to produce and release the antibodies against these compounds that are used to 
diagnose celiac disease – antigliadin, antiendomysial, and tissue transglutaminase.3 The autoimmunity 
in CD involves plasma cells that produce IgA and IgG which are directed at these antigens.  There is 
little or no involvement of IgE. Elimination of gluten from the diet is the only way to remove the T-cell 
response that is essential for the B-cell production of antibodies against tissue transglutaminase and 
gliadin.    
For reasons not completely understood, enterocyte damage leads to increased HLA-DQ and tissue 
transglutaminase expression. Naturally with this increased expression, there is also increased cytokine 
response, further perpetuating the destructive cycle. 
It has been shown that with strict dietary compliance, antibody levels can normalize within 6-12 
months and complete histological recovery can take as long as two years.2  
The need for dietary exclusion of gluten has long been recognized and validated with scientific 
research.  What hasn’t been so well substantiated is a defined maximum amount of gluten that still 
allows for intestinal histological recovery and preservation. And with more people being diagnosed, 
increasing availability of gluten-free products, the plethora of products that do contain gluten that are 
not labeled as such, and the known potential consequences of dietary noncompliance, it has become an 
important area of research to understand the complexities of the issues surrounding noncompliance.  
 10 
Purpose of Study 
The purpose of this literature review is to understand the level of precision one needs to sustain on a 
gluten free diet in order to achieve and maintain intestinal histological recovery. How much is too 
much gluten? A secondary goal is to understand the complexities of the issues surrounding 
noncompliance. So much information is available on a GFD, why do so many people fail to comply? 
Methods 
An online search was performed using Ovid, PubMed, as well as UpToDate and references were 
investigated and sought out as they were relevant. Keywords used were: celiac disease, gluten-free 
diet, gluten threshold, quality of life, dietary compliance. 
Two of the main articles were used to examine available information on a gluten threshold as it relates 
to intestinal integrity. They compared ingestion of known varying amounts of gluten with serological 
and histological evaluation to determine if there was a definable threshold for daily gluten ingestion 
while still maintaining intestinal histological integrity.  
Two more articles try to establish reasonable maximum amounts of allowable gluten in foods claiming 
to be gluten-free. 
Four more articles focused on quality of life issues for patients attempting to follow a gluten-free diet. 
Three of these studies concentrate on the psychosocial issues impacting compliance and one study 
focuses on the financial burden following a gluten-free diet.  
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Results 
A Review of the Literature 
Gluten Threshold as Related to Intestinal Integrity 
Study One: Intestinal Permeability in Long-Term Follow-up of Patients with Celiac Disease on a 
Gluten-Free Diet.4 
Purpose of the Study: To determine the correlation between gluten ingestion and intestinal 
permeability as well as serologic markers, specifically IgA EMA. 
Methods: Participants were between the ages of 24-78 with biopsy confirmed CD who have shown a 
clinical response to a GFD. Others included were those with clinical presentations consistent with CD, 
positive IgA EMA, and clinical response to a GFD.  Control group participants were included if they 
had no history of gastrointestinal disease and no recent use of aspirin of non-steroidal anti-
inflammatory medications. Participants were divided into one of four groups: Group A, on a GFD for 
less than one month; Group B, on a GFD for 1 month to 1 year; Group C, on a GFD for over 1 year; 
Group D, Control group.  
Control participants had permeability testing done on two separate occasions, 4-12 weeks apart. Group 
A would have one permeability test prior to beginning the gluten-free diet. Groups B and C would 
have permeability and IgA EMA testing as well as a detailed dietary evaluation all done on two 
separate occasions, 4-12 weeks apart. 
All participants ingested a solution of 5 grams lactulose, 2 grams mannitol, and 100 grams sucrose in 
300 milliliters of water after fasting overnight. Urine was collected for 5 hours in a preservative of 5 
milliliters of 10% thymol in methanol. Participants were permitted to eat any food not containing 
sucrose after the first two hours. Water was permitted throughout. The fractional excretion of lactulose 
and mannitol were calculated.  
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Dietary evaluation consisted of a three day food record, one weekend day and two week days, as well 
as one random 24 hour recall. This was evaluated by a registered dietitian experienced in celiac disease 
and rated as one of the following: (N) no gluten ingested, (T) trace gluten ingested (i.e. malt), (G) 
significant gluten ingested (more than food additives). Participants also specified brand of food 
consumed so that food labels could be examined and product manufacturers could be contacted to 
better estimate exact amounts of gluten content.  
Results: Total number of participants used for analysis were Group A (3), Group B (9), Group C (42). 
Participants were excluded for not completing second permeability test (3), unquantifiable 
occupational gluten exposure (1), alcohol consumption within 24 hours of permeability test (6), non-
steroidal anti-inflammatory ingestion (4), and ingestion of gum containing mannitol (3). 
Groups A and B illustrated mostly abnormal permeability testing with the only difference being that 
Group B showed a trend  toward an improved result when compared to Group A. Group C results 
suggested normalization after following a GFD for more than one year in 80% and 87% for visit 1 and 
2, respectively.  
When comparing participants by gluten ingestion, there was a significant correlation between gluten 
ingestion and positive IgA EMA on the first visit when compared to no gluten ingestion.  
Conclusions: Figure I shows the trends of IgA EMA and intestinal permeability when comparing no 
gluten, trace gluten, and significant gluten intake. The overall results of this study would suggest that 
strict adherence to a gluten free diet will afford improved intestinal integrity and serologic results.  
Validity: Intestinal permeability testing was not validated in this particular study, but it has been 
validated by other studies. Limitations of this study would be the low number of participants and the 
degree of precision one needs to maintain with regards to the amount of gluten in the diet.  
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Study Two: A Prospective, Double-Blind, Placebo-Controlled Trial to Establish a Safe Gluten 
Threshold for Patients with Celiac Disease.5 
Purpose of the Study: To determine a safe threshold of gluten exposure as it relates to intestinal 
mucosal integrity. 
Methods: This was a prospective, multicenter, placebo-controlled, double-blind, randomized trial done 
in Italy between 2001 and 2004. The study included forty-two patients with biopsy proven CD who 
had maintained a GFD for at least two years. Patients had to be at least 18 years old, maintain 
compliance to GFD, have negative serology for IgA tTG, and have villous height/crypt (Vh/Cd) depth 
greater than 1.5 micrometers.  Patients with IgA deficiency were excluded and control patients were 
adults negative for serologic indices for CD. 
After being screened and undergoing a dietary interview, qualifying patients in the trial were required 
to follow a strict GFD, buying only gluten free products available on the market in Italy, as Italian law 
states gluten contamination is anything greater than 20 ppm.  Patients returned for baseline evaluation 
after one month which included dietary evaluation, IgA tTG testing and endoscopy with small bowel 
biopsy. Patients were then randomly assigned to three different groups where they would ingest a 
given capsule for the next 90 days while maintaining strict adherence to a GFD.  Each group was given 
a capsule containing either 10 mg purified gluten, 50 mg purified gluten, or 50 mg cornstarch as a 
placebo. At the end of the three month microchallenge, patients repeated the dietary interview, 
serologic testing and small bowel biopsy.  If patients showed any signs and symptoms of CD relapse 
during the microchallenge, they were asked to undergo the same evaluation prior to stopping the 
protocol. 
 Purified gluten was used in a gelatin capsules for quick dissolution in the stomach, which were 
prepared by the pharmacy of the Università Politecnica delle Marche, Ancona, Italy. Biopsy 
specimens, laboratory tests and analyses were all performed in the same location. Biopsy specimens 
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were examined for villous height/crypt depth and intraepithelial lymphocyte count by two pathologists 
experienced in morphometric analysis. 
Background intake of gluten was analyzed for gluten contamination. Participants were asked to report 
the brand and amount of gluten-free product they consumed during a 30 day period. Forty-two 
different products were randomly selected from this sample and analyzed  for gluten content using 
ELISA measuring no lower than 3 ppm of gluten.  
Results: Thirty women and 9 men completed the study protocol. Participants followed a GFD for a 
median time of 10.1 years. There were 20 controls, 13 challenged with placebo, 13 with 10 mg gluten 
per day, and 13 with 50 mg gluten per day.  
 There were no significant changes among the three groups regarding clinical outcomes when 
comparing baseline and post-challenge. There was no significant change in IgA tTG after the 
microchallenge in any of the three groups. Small bowel biopsy at baseline showed a significantly lower 
Vh/Cd in the CD participants when compared to controls as well as significantly higher intraepithelial 
lymphocyte count (Table I). After the microchallenge, a significant difference was noted between the 
50 mg group and the placebo group with regards to Vh/Cd ratio as there was a 85% improvement in 
the placebo group and only a 15% improvement in the 50 mg group. 
Conclusions: While the study population was limited, the results suggest that 50 mg of daily gluten 
ingestion is sufficient enough to cause a significant decrease in Vh/Cd ratio in patients with CD. It is 
shows significant improvement in Vh/Cd ratio with strict adherence to a GFD in the placebo group. It 
confirmed findings from previous studies that serological markers are not sensitive enough to detect 
minor relapses in diet adherence as residual enteropathy can be present with negative serologic 
markers.  
Validity: Positive aspects of this study were that is was double-blind, placebo-controlled, and patients 
were randomized into their study groups. Food types were randomly selected for analysis and diets 
were scrutinized for gluten content. The study measured what it intended to measure. Limitations were 
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the small study population and the lack of description of how the diets were scrutinized and what was 
done with that information.  
Gluten Threshold as Related to Gluten-Free Products 
Study One: Consumption of Gluten-Free Products: Should the Threshold Value for 
Trace Amounts of Gluten be at 20, 100, or 200 p.p.m.?1 
Purpose of the Study: To ascertain gluten exposure through examination of questionnaires kept by 
celiac patients then using this in the collaborative effort to establish safe levels of gluten in the diet.  
Methods: Questionnaires were developed and sent to celiac societies in Italy, Spain, Norway, and 
Germany in order to modify them with regards to language and regional food choices. They were then 
mailed with self addressed stamped envelopes to 36,000 individuals in Italy, 5,000 in Spain, and 7,500 
in Norway. The questionnaire was announced on a celiac society website and returned via email in 
Germany. Each participant weighed the gluten-free products prior to consumption and recorded weight 
of the food and amount consumed in two different tables. Those not recording the weight and amount 
properly were excluded from the analysis.   
Results: Total number of respondents: 1359 from Italy, 273 from Spain, 226 from Norway, and 56 
from Germany. Bread was the most consumed gluten-free product across the board. The results of this 
study are reported in percentiles as it relates to total daily gluten intake in grams (see Figure II). The 
total daily intake in the 90th percentile for all four countries ranged from 400 to 531 grams of gluten. 
The range for the 50th and 10th percentiles were 173 to 268 and 91 to 152, respectively. Table II 
compares gluten exposure as calculated according to various regulating agencies with three different 
levels of gluten threshold. If regulations required a set maximum level of 20 ppm in order for food to 
be claimed as gluten-free, participants in this study would have consumed the equivalent of 8 to 20.1 
mg of gluten per day. If the level was set at 100 or 200 ppm, daily intake would have been the 
equivalent of 40 to 100.4 and 80 to 201 mg of gluten per day, respectively.  
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Conclusions: It is both time consuming and expensive to determine the amount of gluten ingested on a 
daily basis. This particular study attempted to measure the amount of gluten ingested from specified 
gluten-free products. This does not take into account other food sources that may contain gluten 
outright or via contamination due to processing. What little research is available suggests that as little 
as 50 mg of gluten a day is sufficient enough to cause intestinal mucosal histological changes. Given 
this information, only the participants under 20 ppm would be protected.  
Validity: The questionnaire was designed by three pharmacists, one dietitian, one nutrition and food 
science expert, and one statistician from the University of Barcelona. Explicit instructions were given 
on the format of filling out the diaries and were tested on 10 study participants to verify clarity of 
instructions. Participants who did not complete the questionnaire correctly were not included in the 
statistical analysis.  
 
Study Two: The Safe Threshold for Gluten Contamination in Gluten-Free Products. Can Trace 
Amounts be Accepted in the Treatment of Coeliac Disease?6 
Purpose of the Study: Establish a practical maximum amount of gluten allowable in foods claiming to 
be gluten-free.  
Methods: Various gluten-free food samples were gathered and analyzed for gluten content using a 
method called the sandwich ELISA. This particular test was limited to 10 ppm gluten. Two flours were 
examined for comparison: wheat starch based gluten-free flour and naturally gluten-free flour.  Four 
day food records were examined for 76 adults and 16 children with CD who have been gluten-free 
ranging from 1-10 years.  
Results: Trace amounts of gluten were found in naturally occurring gluten free foods and five were 
found to contain 100 ppm gluten. None exceeded 200 ppm. Table III shows a comparison of varying 
amounts of gluten-free food intake with the proposed gluten limit (ppm) to indicate what the potential 
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total daily gluten load would be. If daily intake remains less than 300 grams and the gluten limit is set 
at 100 ppm, daily maximum gluten would be 30 mg from gluten-free foods. As a reference, six slices 
of bread is approximately 100 grams of baking mix.  
Conclusions: Research has suggested that 30 mg daily gluten intake is a reasonable limit while still 
maintaining intestinal mucosal integrity. While this study did not focus on histological changes, it 
provided a better indication of how much gluten is coming from supposedly gluten-free foods.  
Validity: Gluten analysis was done using a widely used testing method, the sandwich ELISA. 
Seventy-six participants is a relatively small number to evaluate, although there are very few studies 
available. There was no indication as to any instructions that may have been given to participants 
regarding the procedure for filling out the food record. This study would suggest that while the amount 
of ingested gluten may not be entirely accurate, information presented on the amount of gluten in 
gluten-free foods is likely close. 
 
Gluten Free Diet as Related to Quality of Life 
Study One: Self-Rated Quality of Life in Celiac Disease.7 
Purpose of the Study: To evaluate quality of life as perceived by the adult celiac patient after 
following a gluten-free diet for at least one year. 
Methods: Members of five regional celiac societies of Italy were solicited for participation. The only 
requirement was GFD adherence for at least the past 12 months. The questionnaire was standardized 
and self-administered. Participants’ perceptions were elicited by exploring their knowledge of the 
disease and diet as well as their compliance to the GFD. This was done using the visual analog scale 
(VAS) rated 0-20. Other aspects evaluated were anxiety, depression, and positive attitude by summing 
4-5 visual analog items. 
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Results: Total participants: 410 females and 171 males, with a mean age of 31.5 years and a mean age 
of diagnosis of 23 years.  
Knowledge About Celiac Disease: 96.9% correctly identified CD as a chronic food intolerance, 3.7% 
thought gluten ingestion was harmless, 43.8% considered it very harmful, 39.5% knew that ingestion 
could cause clinical symptoms, 82% knew of the genetic risks, and 83% were familiar with the 
diagnostic procedures. 
The Gluten-Free Diet Compliance: 74.1% of the participants reported total adherence, 21.5% were 
fairly adherent (1-3 transgressions/month), and 4.4% continually transgressed. Using the VAS scores 
(reported as median scores using range 0-20), the reasons for diet non-adherence were: problems 
ordering in restaurants (6.51), feeling of anger toward celiac disease (5.95), not to be different from 
others (5.38), and the hope that occasional transgressions is not very harmful (5.91). With regards to 
eating out and parties, 15% “often” or “very often” were embarrassed to ask for gluten-free foods. 
Table IV illustrates difficulties of dietary compliance in a social setting. 
Feelings of Well-Being: Using the VAS scores, the overall feeling of well-being was rated as 6.82. 
Table V shows the distribution of anxiety, depression, and happiness as it is broken down into rarely, 
sometimes, often, and very often. Regarding the “sometimes” and “often” categories, anxiety was 
experienced by 30.8% and 11.9%, respectively. Depression was 19.3% and 5.8%, respectively. 
Happiness was reported as “rarely” by 45.8% of the participants.  
Correlation Among Factors: Diet adherence was better among females and for those diagnosed after 
the age of 20. Those diagnosed after the age of 20 also had better overall feelings of well-being. No 
correlation was noted between sex or age and depression and anxiety scores. Men and those diagnosed 
in childhood scored slightly better on the happiness scale.  
Conclusions: The amount of uneasiness and embarrassment was a significant influence on diet 
adherence. The study shows that females, while scoring higher on dietary compliance, score lower on 
level of well-being. It raises the question, is there a price for dietary compliance? It is encouraging to 
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see high ratings on quality of life with CD even if it does not represent our population in the United 
States.  
Validity: There is an obvious selection bias as all participants came from celiac societies of Italy. 
While this may not be representative of the general celiac population, it likely represents the best case 
scenario for celiac patients as this group is motivated enough to attend society meetings. Of note, 22% 
of those who declined to participate had low or very low dietary compliance. However there was a 
78% response rate to the self-administered questionnaire. There was no control group as this may not 
have been an appropriate comparison.  
 
Study Two: The Impact of a Gluten-Free Diet on Adults with Coeliac Disease: Results of a National 
Survey.8 
Purpose of the Study: To determine the impact of following a gluten-free diet on quality of life. 
Methods: A 76 question survey was mailed to Canadian Celiac Association members along with a 
letter of explanation and a self-addressed stamped envelope. The survey included questions relating to 
GFD as well as quality of life issues. The Short Form 12 (SF-12) was used to evaluate quality of life.  
Results: There was a 65% response rate (n=3408). Excluded from analysis were 504 who did not have 
biopsy proven CD and 55 who did not complete the questionnaire properly. 2681 adults were analyzed 
along with 161 children (under 16 years). Females represented 74.5% of the adult participants and 
males 25.5% with a mean age of 56 years. Mean age of diagnosis was 46 years. Only 7% of the 
participants were diagnosed as children.  
Ninety percent of the participants described their diet as strictly gluten-free and 8% reported being 
partially gluten-free. After initiating a gluten-free diet, 83% felt their health ‘improved a lot’, 13% felt 
moderate improvement, 3% felt little improvement, and 1% felt no improvement. 
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There were many factors identified in the difficulties of diet adherence: eating outside the home, 
finding gluten-free foods while travelling, determining gluten content of foods, and feelings of 
isolation in social settings. Table VI summarizes the breakdown. 
Conclusions: Quality of life could be improved with better gluten-free product availability as well as 
improved labeling. Better dietary instruction and various celiac societies may be a good way to 
improve understanding and ease anxieties surrounding celiac disease. 
Validity: The survey was developed by the Professional Advisory Board of the Canadian Celiac 
Association in collaboration with the Department of Epidemiology and Community Medicine of the 
University of Ottawa and two international experts in CD evaluated the questionnaire. Sample 
population may be a biased representation as they are all from a celiac society, however it provides a 
good look at quality of life of those actually adhering to the required diet.  
 
Study Three: Celiac Diet: Its Impact on Quality of Life.9 
Purpose of the Study: To determine the impact of following a gluten-free diet on quality of life. 
Methods: Self administered 29 item questionnaires were mailed out with self addressed stamped 
envelopes to 404 members of the Westchester Celiac Sprue Support Group. The questionnaire covered 
demographics, lifestyle, and food choices. Specific questions were chosen to explore self perceptions 
of health and impact of CD on ability to work as well as social issues. There were 274 questionnaires 
returned, a 68% return rate, however 20 responders were under 18 and were not used as consent was 
not sought.  
Age ranged from 18-55 with 74% female and 26% male participants. All participants resided in 
suburban to semirural areas in New York state with 46% being 55 years of age or older.  
Results: Prior to starting a GFD, 49% of participants felt their health was ‘good’. After maintaining 
the diet, 60% felt they were as healthy as anyone else.  
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The majority of participants (81%) reported CD had no effect on their ability to work however 41% 
felt that maintaining a GFD negatively impacted their careers. Table VII depicts the various areas of 
impact and how much they affect quality of life. Overall, more women reported feeling negatively 
affected by the various areas of daily living. When it comes to dining out, 65% of women felt 
negatively impacted by maintaining a GFD versus 20% of men. Forty-nine percent of women felt 
maintaining their diet negatively their family where only 18% of men felt the same way.  
Conclusions: This study presents strong evidence that maintaining a GFD negatively impacts quality 
of life for those with CD. This study also suggests, as many others do, that women are more often 
affected than men. This supports the need for better availability of gluten-free products as well as 
better understanding of the disease and the gluten-free diet itself. 
Validity: The survey was approved by the Queens College Institutional Review Board. This study 
represents only those from a celiac support group. This allows for good representation of celiac 
patients who are more likely to adhere to the required diet, therefore giving a more accurate depiction 
of its affect on quality of life. 
 
Study Four: Economic Burden of a Gluten-Free Diet.10 
Purpose of the Study: To determine the economic burden of adhering to a gluten-free diet.  
Methods: A “market basket” of products was developed and evaluated for cost difference for both 
type of product and for region of the country. Food products were either the regular, wheat based 
product or the gluten-free equivalent. The “market basket” was derived from four different online 
stores, local grocery stores, upscale grocery stores or regional small chain, and health food stores. 
These stores were assessed in five different states in order to evaluate any regional difference that may 
exist. Prices were obtained by store visitation. Price comparisons are reported in price per ounce.  
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Results: Regular wheat-based and gluten-free product availability varied among the shopping venues. 
The regular wheat-based products were available in all venues across all five regions. Gluten-free 
products had highest availability in the health food and online stores. Availability of gluten-free 
products across the board was 100% for online stores, 94% health food stores, 42% upscale grocery 
stores, and 36% for local grocery stores. New York states had the greatest overall availability of 
gluten-free products.  
For cost comparison, gluten-free products were about 123% more expensive in the health food stores 
than any other venue. Online stores were the most expensive overall but were not statistically 
significant due to the small sample size. Table VIII outlines the availability and cost comparison for 
the venues investigated. 
Geographic location did not seem to affect cost but did so for availability. Every gluten-free product 
was more expensive than the regular wheat-based equivalent (Table IX). The average cost increase was 
240% more. 
Conclusions: Studies have been done on the increased cost of eating a healthier diet but none have 
evaluated the costs incurred maintaining a GFD. The increase in cost of healthier diets, which was 
attributed to higher amounts of fruits, vegetables, and meat, would be the same for a GFD as they are 
naturally gluten-free. The significant increase in cost that this study evaluated was only for gluten-free 
products. The additional cost of fruits, vegetables, and meat was not factored in to the assessment of 
the financial burden. Product availability varied across the regions. While price varied, the only 
products with statistical difference in price were pasta and bread. Generally speaking, gluten-free 
products cost about three times their regular wheat-based counterparts. 
Validity: The ‘market basket’ looked at several different regions as well as venues and looked at 
products taken from the United States Department of Labor, Bureau of Labor statistics. The raw cost 
was then broken down into per ounce pricing for easier comparison.  
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Conclusion  
Adapting to celiac disease and a gluten-free diet is a potentially long process. Knowing how much 
gluten is actually being ingested is difficult but soon there will be new labeling laws in the United 
States using 20 ppm as the cutoff for gluten-free foods. That being said, eating 1000 grams of gluten-
free product with a set gluten limit of 20 ppm, actual gluten ingestion would be approximately 20 mg, 
which research suggests is a nontoxic level. Research has shown that as little at 50 mg per day of 
gluten ingestion is enough to cause intestinal histological changes. Maintaining a diet consisting 
mostly of fruits, vegetables, and meat with the addition of moderate amounts of gluten-free alternatives 
for breads, pastas, crackers, etc. will then likely be safe. Becoming a member of a celiac support group 
is an excellent way to gain a better understanding of the disease but more importantly the intricacies of 
the required diet. Scrutinizing labels for hidden sources of gluten is stressful but necessary and having 
the help and support of experts can make this process a little easier. And finally, follow-up with a 
primary care provider is strongly recommended as antibody levels need to be monitored periodically as 
well the potential need for an additional small bowel biopsy. 
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Tables 
Table I 
 
Table II 
 
 
 
 
TABLE 1 5 
Intestinal morphometric evaluation of the subjects before and after the gluten microchallenge1 
 
 CD patients at   
                                                             Control subjects  baseline   
                                                                  (n = 20)  (n = 39)  P2  
Villous height (_m)                      372.7 (339.5, 385.4)                 354.3 (318.0, 380.5)                    0.130  
Crypt depth (_m)                     135.1 (124.8, 149.7)                  150.9 (134.9, 160.6)                    0.077  
Vh/Cd                     2.9 (2.5, 3.1)                              2.2 (2.1, 2.9)3                              0.019  
IEL count (_100                     22 (18, 24)                                 27 (23, 34)3                                 0.002  
enterocytes)   
1 All values are medians; 95% CIs in parentheses. CD, celiac disease;  
Vh/Cd, villous height/crypt depth; IEL, intraepithelial lymphocyte.  
2 The Wilcoxon test was used for the comparison between groups.  
3 Significantly different from the control subjects, P < 0.05.  
 Italy (n=1359) Spain (n=273) Norway (n=226) Germany (n=56) 
Percentiles of daily intake (g) 
 90th 95th 97.5th 90th 95th 97.5th 90th  95th 97.5th 90th 95th 97.5th 
 531.2 639.4 1003.7 404.0 512.2 717.2 411.6 512.1 638.3 400.1 487.3 505.7 
 Daily amount of gluten exposure (mg) 
Gluten Threshold 
(ppm) 
           
20 10.6 13.9 20.1 8.1 10.2 14.3 8.2 10.0 12.8 8.0 9.3 10.1 
100 53.1 69.5 100.4 40.4 51.2 71.7 41.2 50.2 63.8 40.0 45.7 50.6 
200 106.2 139.3 201.0 80.8 102.4 143.4 82.3 100.4 127.7 80.0 93.5 101.1 
Daily gluten exposure deduced from the different percentiles of consumption of gluten-free products and the 
different thresholds of gluten contamination1 
 25 
 
Table III 
 
 
Table IV 
 
 
 
 
 
 
 
 
 Amount of daily gluten-free foods (grams) 
Gluten content in products, 
 ppm = mg/kg 
50 100 200 300 
 Amount of daily ingested gluten (mg) 
200 10 20 40 60 
100 5 10 20 30 
50 2.5 5 10 15 
20 1 2 4 6 
Estimated amount of daily ingested gluten from different amounts of gluten-free foods with varying glute  
contamination. Six slices of bread correspond to approximately 100 g baking mix.6 
Difficulties in Social Life7 
 N % 
Feeling Uneasy at Table   
  Never 155 26.4 
  At parties 161 27.5 
  At refectories 84 17.0 
  Several occasions 150 25.6 
Feeling Uneasy   
  Never 253 46.3 
  Sometimes 182 33.3 
  Often 55 10.1 
  Very often 57 10.4 
Feeling Different   
  Never 236 44 
  Sometimes 218 40.7 
  Often 49 6.2 
  Very often 33 6.2 
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Table V 
 
 
Table VI 
 
 
 
Mood Attitudes7 
 Anxiety Depression Happiness 
 N % N % N % 
Rarely 332 56.6 436 74.3 269 45.8 
Sometimes 181 30.8 113 19.3 193 32.9 
Often 70 11.9 34 5.8 110 18.7 
Very often 4 0.7 4 0.7 15 2.6 
Impact of a Gluten-Free Diet11 
 All of the 
time (%) 
Most of 
the time 
(%) 
Some of 
the time 
(%) 
Never 
(%) 
N/A or 
do not 
know 
N 
Brought gluten-free foods when 
travelling  
53 22 19 6 0.2 2590 
Avoided restaurants 6 27 48 19 - 2631 
Had difficulty finding good quality 
gluten-free foods 
8 22 53 17 - 2597 
Had difficulty finding gluten-free foods 6 19 60 15 - 2608 
Could not determine if foods were 
gluten-free 
5 13 67 15 - 2631 
Avoided travelling 3 10 25 62 0 2611 
Worried about staying in hospital 
because of CD 
8 5 14 72 1 2546 
Felt left out of meal invitations because 
of CD 
2 6 28 63 1.0 2591 
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Table VII 
Impact of gluten-free diet on quality of life.9 
Area of 
Impact 
Has some impact (%)_____ Had no impact (%)_______ 
 Total Women Men Total Women Men 
Dine out 86 65 20 14 12 2 
Travel 82 64 18 18 14 4 
Family 67 49 18 33 29 4 
Work/career 41 26 15 59 50 9 
N=254; Self-reported perception. 
 
Table VIII 
 
 
The availability and cost of gluten-free products across USA region and venue10 
 New York_____ Atlanta______ Chicago______ South Dakota__ Portland______  
Food R H US R H US R H US R H US R  H US Int 
Bread n/a 0.18 0.17 n/a 0.29 0.21 n/a 0.19 0.15 n/a 0.23 0.24 0.25 0.25 0.24 0.23 
Muffin n/a n/a 0.39 n/a n/a n/a n/a 0.23 0.22 n/a 0.28 n/a n/a 0.25 n/a 0.57 
Cereal 0.29 0.33 0.33 n/a n/a 0.31 0.29 0.33 0.31 0.42 0.34 0.33 0.31 0.29 n/a 0.27 
Waffle 0.39 0.37 0.25 n/a 0.38 0.33 n/a n/a 0.27 n/a 0.27 0.38 0.37 0.3 n/a 0.42 
Crackers 0.89 0.68 0.54 n/a 0.63 n/a n/a 1.83 n/a 0.37 0.5 0.48 0.40 0.44 n/a 0.75 
Cookies n/a 0.51 0.41 n/a 0.42 n/a n/a 0.42 0.5 0.60 0.84 0.68 0.77 0.08 n/a 0.48 
Pretzels n/a 0.41 0.37 n/a 0.68 n/a n/a n/a n/a n/a 0.31 0.71 0.64 n/a n/a 1.09 
Pasta 0.18 0.19 0.17 n/a 0.32 n/a n/a 0.23 0.22 n/a 0.40 0.27 0.34 0.27 n/a 0.27 
Pizza n/a 0.60 0.52 n/a n/a 0.34 n/a n/a 0.56 n/a 0.64 n/a n/a 0.52 n/a 0.38 
Mac/cheese n/a 0.33 0.28 n/a n/a 0.35 n/a 0.45 0.3 n/a 0.28 n/a 0.32 0.33 n/a 0.42 
Cake n/a n/a 0.67 n/a n/a n/a n/a n/a 0.64 n/a 0.44 n/a 0.32 0.42 n/a 0.49 
The exchange rate at the time of the survey ranged from 1.7507 to 1.7944 with an average rate of 1.77255 US 
dollars to British pounds. Price is expressed as dollar per ounce.  
N/a, not available; R, local grocery store chain; H, small chain and health food store; US, upscale grocery stores; 
Int, online stores. 
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Table IX 
 
 
 
 
 
 
 
 
 
 
 
National comparison of regular and gluten-free products10 
Food (price/oz) Regular Gluten-Free P-value 
Bread 0.15 0.23 0.00 
Cereal  0.32 0.35 0.27 
Waffles 0.27 0.35 0.05 
Crackers 0.36 0.78 0.00 
Cookies 0.34 0.51 0.00 
Pretzels 0.34 0.77 0.01 
Pasta 0.11 0.24 0.00 
Pizza 0.33 0.55 0.00 
Mac/cheese 0.25 0.34 0.01 
cake 0.31 0.86 0.12 
Significant at a 5% confidence interval excluding cereal and cake. 
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Figures 
Figure I 4 
          
Percentage positive results of intestinal permeability (IP) and endomysial antibody (IgA EMA) in each 
dietary category. Visit 1 and Visit 2, respectively. 
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Appendix A 
 
Gluten-free Grains, Flours, and 
Starches  
Gluten-containing Grains, Flours, 
and Starches  
Amaranth  Barley  
Arrowroot  Bulgar  
Bean flours (garbanzo, fava, romano)  Cereal binding  
Buckwheat  Chapatti flour (atta)  
Corn  Couscous  
Fava  Dinkel  
Flax seed  Durum  
Garbanzo beans  Einkorn  
Garfavaa flour (garbanzo_fava bean)  Emmer  
Hominy  Farina  
Mesquite flour  Farro  
Millet  Fu  
Montinab flour  Gluten, gluten flour  
Nut flour and nut meals  Graham flour  
Oats (uncontaminated)  Kamut  
Peas flour  Malt (malt extract, malt flavoring, malt 
syrup, malt vinegar)  
Potato flour, potato starch  Matzoh meal  
Quinoa  Oats (most commercial brands, oat 
bran, oat syrup)  
Rice, all forms (brown, white, sweet, 
wild, jasmine, basmati,  
Orzo  
glutinous rice, rice polish, rice bran)  Rye  
Sago  Seitan (aka wheat meat)  
Sorghum flour  Semolina  
Soy flour  Spelt  
Tapioca (manioc, cassava, yucca)  Triticale  
Teff (or tef) flour  Wheat (bran, germ, starch)  
Gluten-free and gluten-containing grains, flours, and starches. Originally developed by Authentic 
Foods Company, Gardena, CA. Amazing Grains Grower Cooperative, Ronan, MT. Adapted from 
Case S. Gluten-Free Diet: A Comprehensive Resource Guide. Regina, Saskatachewan, Canada: 
Case Nutrition Consulting; 2006, with permission, and Raymond N, Heap J, Case S. The gluten-
free diet: An update for health professionals. Pract Gastroenterol. 2006; 30:67-92, with permission.2 
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Appendix B 
Online Resources2 Books 
Quick Start Diet Guide: Celiac Disease Foundation (CDF) & Gluten 
Intolerance Group (GIG) 
www.celiac.org, www.gluten.net 
Celiac Disease: A Hidden Epidemic 
by Peter Green, MD, and Rory Jones. Harper Collins Publishers, 
2006. 
www.harpercollins.com 
American Celiac Disease Alliance 
www.americanceliac.org  
Celiac Disease Nutrition Guide, American Dietetic Association: 
2nd ed, 2006 
by Tricia Thompson, MS, RD 
www.eatright.org 
  
American Dietetic Association (ADA) 
www.eatright.org 
Canadian Celiac Association (CCA) 
www.celiac.ca  
Gluten-Free Diet: A Comprehensive Resource Guide, Regina, 
Saskatchewan, Canada 
by Shelley Case, RD. Case Nutrition Consulting, 2006. 
www.glutenfreediet.ca 
Celiac Disease and Gluten-Free Diet Support Center  
www.celiac.com   
Celiac Disease Center at Beth Israel Deaconess Medical Center  
www.bidmc.harvard.edu/celiaccenter Guidelines for a Gluten-free Lifestyle, 3rd ed. Celiac Disease  
Celiac Disease Center at Columbia University 
www.celiacdiseasecenter.columbia.edu  
Foundation. www.celiac.org (1)Kids with Celiac Disease: A 
Family Guide to Raising Happy,  
Celiac Disease at Mayo Clinic  
www.mayoclinic.org/celiac-disease  
Healthy, Gluten-Free Children; (2)Wheat-Free, Worry-Free: The 
Art of Happy, Healthy, Gluten-Free Living  
Celiac Sprue Association (CSA) 
 www.csaceliacs.org  
by Danna Korn. Hay House, Inc. www.glutenfreedom.net  
Center for Celiac Research at University of Maryland 
www.celiaccenter.org  
Pocket Dictionary: Acceptability of Foods and Food Ingredients 
for the Gluten-Free Diet. Canadian Celiac Association. 
www.celiac.ca  
Children’s Digestive Health and Nutrition Foundation: Celiac Disease  
Resources  
www.celiachealth.org 
 
 
Food Allergen Labeling and Consumer Protection Act of 2004 
(FALCPA)  
www.cfsan.fda.gov/_dms/alrgact.html  
 
 
Gluten Free Living: National Newsletter for People with Gluten 
Sensitivity  
gfliving@aol.com  
 
 
Living Without Magazine  
www.livingwithout.com  
 
 
National Institutes of Health Celiac Awareness Campaign  
http://celiac.nih.gov/  
 
 
National Institutes of Health Consensus Development Conference on  
Celiac Disease  
http://consensus.nih.gov/2004/2004celiacdisease118html.htm  
 
 
 
University of Chicago Celiac Disease Program  
www.celiacdisease.net  
 
 
University of Southern California Keck School of Medicine  
Center for Celiac Research-West  
www.glutenfreemd.com  
 
 
 
University of Virginia Digestive Health Center of Excellence-Celiac 
Disease  
www.healthsystem.virginia.edu/internet/digestivehealth/nutrition/  
celiacsupport.cfm  
 
 
 
Wm. K. Warren Medical Research Center for Celiac Disease  
Clinical Celiac Disease Center at the University of California, San Diego  
www.celiaccenter.ucsd.edu  
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